Skip Navigation Links
Skip Navigation Links


MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma. EAY131 (NCT02465050)  (MBMC Contact: Missy Kuhn 314-996-5868) 

A randomized phase III trial of hypofractionated post-prostatectomy radiation therapy (HYPORT) versus conventiona post-prostatectomy radiation therapy (COPORT) NRG-GU003 (NCT01492972) (MBMC Contact Missy Kuhn 314-996-5868) (Pending RT credentialing for MBMC, SE, and Cap Reg)

Androgen deprivation therapy and high dose radiotherapy with or without whole pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancaer:  A phase III randomized trial
 NRG RTOG 0924 (NCT01368588)  (MBMC Contact Missy Kuhn 314-996-5868)

Prostate Cancer Trials in St. Louis, MO

All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy